India’s Piramal Life Considers New Ties To MNCs
This article was originally published in PharmAsia News
Executive Summary
Piramal Life Sciences of India is considering agreements with multinational drug makers in research on anti-inflammation and infectious-disease drugs. Piramal Life, which already has formed similar arrangements in cancer and diabetes research, now is considering talks with other companies about joint efforts in the other two areas. CEO Somesh Sharma said the talks are part of the firm's policy to consider "mutually beneficial research alliances." (Click here for more